Table 2.
Changes in lipid levels in individuals with and without resolution of NASH (N=222)
| Lipid type and cutoff for dyslipidemia | Resolution of NASH at 96 weeks
|
P* | Adjusted P† | |
|---|---|---|---|---|
| Resolved (N=77) | Not resolved (N=145) | |||
| Total cholesterol (mg/dL) | ||||
| Mean (95% CI) | ||||
| Baseline | 192.0 (182.4, 201.5) | 200.9 (194.8, 207.0) | 0.10 | 0.17 |
| 96 weeks | 185.7 (176.1, 195.4) | 186.9 (180.7, 193.1) | 0.83 | 0.98 |
| Change from baseline | −6.2 (−14.7, 2.2) | −14.3 (−20.2, −8.4) | 0.12 | 0.31 |
| N (%) >200 mg/dL | ||||
| Baseline | 36 (46.8%) | 72 (49.7%) | 0.68 | 0.96 |
| 96 weeks | 26 (33.8%) | 50 (35.2%) | 0.83 | 0.77 |
| Change from baseline among dyslipidemics (N=107) | 0.74 | 0.94 | ||
| High at BL/High at 96 wks | 21 (58.3%) | 39 (54.9%) | ||
| High at BL/Normal at 96 wks | 15 (41.7%) | 32 (45.1%) | ||
|
| ||||
| Triglycerides (mg/dL) | ||||
| Mean (95% CI) | ||||
| Baseline | 158.9 (136.3, 181.4) | 174.3 (159.4, 189.3) | 0.25 | 0.29 |
| 96 weeks | 137.8 (121.9, 153.7) | 172.1 (155.8, 188.3) | 0.007 | 0.02 |
| Change from baseline | −21.1 (−37.1, −5.1) | −2.3 (−13.8, 9.2) | 0.06 | 0.03 |
| N (%) ≥150 mg/dL | ||||
| Baseline | 35 (45.5%) | 72 (49.7%) | 0.56 | 0.79 |
| 96 weeks | 24 (31.2%) | 68 (47.9%) | 0.02 | 0.02 |
| Change from baseline among dyslipidemics (N=104) | 0.046 | 0.07 | ||
| High at BL/High at 96 wks | 19 (54.3%) | 51 (73.9%) | ||
| High at BL/Normal at 96 wks | 16 (45.7%) | 18 (26.1%) | ||
|
| ||||
| HDL (mg/dL) | ||||
| Mean (95% CI) | ||||
| Baseline | 44.4 (41.7, 47.2) | 43.2 (41.4, 45.1) | 0.46 | 0.41 |
| 96 weeks | 47.4 (43.6, 51.1) | 40.7 (39.1, 42.4) | <0.001 | <0.001 |
| Change from baseline | 2.9 (0.4, 5.5) | −2.5 (−3.8, −1.2) | <0.001 | <0.0001 |
| N (%) <40 mg/dL (<50 fem.) | ||||
| Baseline | 46 (59.7%) | 96 (66.2%) | 0.34 | 0.83 |
| 96 weeks | 38 (49.4%) | 102 (71.8%) | 0.001 | 0.009 |
| Change from baseline among dyslipidemics (N=140) | 0.005 | 0.009 | ||
| Low at BL/Low at 96 wks | 32 (69.6%) | 84 (89.4%) | ||
| Low at BL/Normal at 96 wks | 14 (30.4%) | 10 (10.6%) | ||
|
| ||||
| LDL (mg/dL) | ||||
| Mean (95% CI) | ||||
| Baseline | 117.1 (109.0, 125.2) | 125.3 (119.8, 130.8) | 0.09 | 0.15 |
| 96 weeks | 112.0 (103.9, 120.1) | 115.2 (109.7, 120.8) | 0.50 | 0.73 |
| Change from baseline | −4.9 (−12.3, 2.6) | −10.7 (−16.3, −5.1) | 0.22 | 0.45 |
| N (%) >130 mg/dL | ||||
| Baseline | 29 (37.7%) | 66 (45.5%) | 0.26 | 0.39 |
| 96 weeks | 19 (24.7%) | 43 (30.3%) | 0.38 | 0.49 |
| Change from baseline among dyslipidemics (N=95) | 0.77 | 0.42 | ||
| High at BL/High at 96 wks | 15 (51.7%) | 32 (48.5%) | ||
| High at BL/Normal at 96 wks | 14 (48.3%) | 34 (51.5%) | ||
|
| ||||
| Non HDL-C (mg/dL) | ||||
| Mean (95% CI) | ||||
| Baseline | 147.5 (138.1,157.0) | 157.7 (151.9,163.5) | 0.06 | 0.10 |
| 96 weeks | 138.4 (129.0,147.7) | 146.2 (140.3,152.1) | 0.14 | 0.25 |
| Change from baseline | −9.2 (−17.1, −1.3) | −11.8 (−17.5, −6.2) | 0.58 | 0.89 |
| N (%) ≥130 mg/dL | ||||
| Baseline | 54 (70.1%) | 112 (77.2%) | 0.25 | 0.24 |
| 96 weeks | 44 (57.1%) | 98 (69.0%) | 0.08 | 0.10 |
| Change from baseline among dyslipidemics (N=164) | 0.39 | 0.73 | ||
| High at BL/High at 96 wks | 40 (74.1%) | 88 (80.0%) | ||
| High at BL/Normal at 96 wks | 14 (25.9%) | 22 (20.0%) | ||
|
| ||||
| Triglycerides/HDL | ||||
| Mean (95% CI) | ||||
| Baseline | 4.1 (3.3, 4.8) | 4.4 (4.0, 4.9) | 0.40 | 0.36 |
| 96 weeks | 3.4 (2.8, 3.9) | 4.6 (4.1, 5.1) | 0.003 | 0.004 |
| Change from baseline | −0.7 (−1.2, −0.2) | 0.1 (−0.2, 0.5) | 0.009 | 0.003 |
| N (%) >5.0 | ||||
| Baseline | 20 (26.0%) | 39 (26.9%) | 0.88 | 0.58 |
| 96 weeks | 17 (22.1%) | 42 (29.6%) | 0.23 | 0.25 |
| Change from baseline among dyslipidemics (N=58) | 0.40 | 0.41 | ||
| High at BL/High at 96 wks | 12 (60.0%) | 27 (71.1%) | ||
| High at BL/Normal at 96 wks | 8 (40.0%) | 11 (29.0%) | ||
*
P-values derived from simple linear or logistic regression models.
†
Adjusted p-values derived from multiple linear or logistic regression models and included treatment group, age at biopsy (years), gender, baseline BMI, ethnicity, statin use at baseline and/or during follow-up, and for change measures, the baseline value of the lipid measure.